Trial Profile
Harnessing Olaparib, Palbociclib and Endocrine Therapy: A Phase I/II Trial of Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer (HOPE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 09 Oct 2023
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Olaparib (Primary) ; Palbociclib (Primary)
- Indications Advanced breast cancer; HER2 negative breast cancer
- Focus Therapeutic Use
- Acronyms HOPE
- 05 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 10 Dec 2021 Trial design presented at the 44th Annual San Antonio Breast Cancer Symposium